Estimates of the annual direct medical costs of the prevention and treatment of disease associated with human papillomavirus in the United States

Vaccine

Volumn 30, Issue 42, 2012, Pages 6016-6019

  Chesson, Harrell W ^a   Ekwueme, Donatus U ^b   Saraiya, Mona ^b   Watson, Meg ^b   Lowy, Douglas R ^c   Markowitz, Lauri E ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cost; Genital warts; Health economics; Human papillomavirus; Intraepithelial neoplasia; Vulvar, vaginal, anal, oral cavity, oropharyngeal, and cervical cancer

Indexed keywords

VIRUS VACCINE;

ANUS CANCER; ARTICLE; CANCER SCREENING; CONDYLOMA ACUMINATUM; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEALTH CARE COST; HUMAN; MALE; MORBIDITY; OROPHARYNX CANCER; PAPILLOMATOSIS; PAPILLOMAVIRUS INFECTION; PENIS CANCER; PRIORITY JOURNAL; RECURRENT DISEASE; UNITED STATES; UTERINE CERVIX CANCER; VAGINA CANCER;

CONDYLOMATA ACUMINATA; COST OF ILLNESS; EARLY DETECTION OF CANCER; FEMALE; HEALTH CARE COSTS; HUMANS; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; RESPIRATORY TRACT INFECTIONS; UNITED STATES; UTERINE CERVICAL NEOPLASMS;

EID: 84865540309     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.07.056     Document Type: Article

References (27)

1. Markowitz L.E., Dunne E.F., Saraiya M., Lawson H.W., Chesson H., Unger E.R. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007, 56:1-24.
2. Gillison M.L., Chaturvedi A.K., Lowy D.R. HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women. Cancer 2008, 113:3036-3046.
3. Markowitz L.E., Hariri S., Unger E.R., Saraiya M., Datta S.D., Dunne E.F. Post-licensure monitoring of HPV vaccine in the United States. Vaccine 2010, 28(July (30)):4731-4737.
4. Saraiya M., McCaig L.F., Ekwueme D.U. Ambulatory care visits for Pap tests, abnormal Pap test results, and cervical cancer procedures in the United States. Am J Manag Care 2010, 16:e137-e144.
5. Eltoum I.A., Roberson J. Impact of HPV testing, HPV vaccine development, and changing screening frequency on national Pap test volume: projections from the National Health Interview Survey (NHIS). Cancer 2007, 111:34-40.
6. Solomon D., Breen N., McNeel T. Cervical cancer screening rates in the United States and the potential impact of implementation of screening guidelines. CA Cancer J Clin 2007, 57:105-111.
7. Insinga R.P., Dasbach E.J., Elbasha E.H. Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature. Pharmacoeconomics 2005, 23:1107-1122.
8. Gamble H.L., Klosky J.L., Parra G.R., Randolph M.E. Factors influencing familial decision-making regarding human papillomavirus vaccination. J Pediatr Psychol 2010, 35:704-715.
9. Ekwueme D.U., Gardner J.G., Subramanian S., Tangka F.K., Bapat B., Richardson L.C. Cost analysis of the National Breast and Cervical Cancer Early Detection Program: selected states, 2003 to 2004. Cancer 2008, 112:626-635.
10. Schabert V.F., Ye X., Insinga R.P., Singhal P.K., Riedel A.A. Five-year routine cervical cancer screening rates and intervals in a US health plan. Curr Med Res Opin 2008, 24:2429-2435.
11. Insinga R.P., Glass A.G., Rush B.B. The health care costs of cervical human papillomavirus-related disease. Am J Obstet Gynecol 2004, 191:114-120.
12. Henk H.J., Insinga R.P., Singhal P.K., Darkow T. Incidence and costs of cervical intraepithelial neoplasia in a US commercially insured population. J Low Genit Tract Dis 2010, 14:29-36.
13. Saraiya M. Burden of HPV-associated cancers in the United States. Meeting of the Advisory Committee on Immunization Practices, Atlanta, GA; February 24, 2011.
14. Hu D., Goldie S. The economic burden of noncervical human papillomavirus disease in the United States. Am J Obstet Gynecol 2008, 198:500-507.
15. Insinga R.P., Ye X., Singhal P.K., Carides G.W. Healthcare resource use and costs associated with cervical, vaginal and vulvar cancers in a large U.S. health plan. Gynecol Oncol 2008, 111:188-196.
16. Kim J.J., Goldie S.J. Health and economic implications of HPV vaccination in the United States. N Engl J Med 2008, 359:821-832.
17. Hoy T., Singhal P.K., Willey V.J., Insinga R.P. Assessing incidence and economic burden of genital warts with data from a US commercially insured population. Curr Med Res Opin 2009, 25:2343-2351.
18. U.S. Census Bureau, Statistical Abstract of the United States: 2011 (130th Edition) Washington, DC; 2010.
19. Armstrong L.R., Preston E.J., Reichert M., Phillips D.L., Nisenbaum R., Todd N.W., et al. Incidence and prevalence of recurrent respiratory papillomatosis among children in Atlanta and Seattle. Clin Infect Dis 2000, 31:107-109.
20. Chesson H.W., Forhan S.E., Gottlieb S.L., Markowitz L.E. The potential health and economic benefits of preventing recurrent respiratory papillomatosis through quadrivalent human papillomavirus vaccination. Vaccine 2008, 26:4513-4518.
21. Bishai D., Kashima H., Shah K. The cost of juvenile-onset recurrent respiratory papillomatosis. Arch Otolaryngol Head Neck Surg 2000, 126:935-939.
22. Derkay C.S. Task force on recurrent respiratory papillomas. A preliminary report. Arch Otolaryngol Head Neck Surg 1995, 121:1386-1391.
23. Lacey C.J., Lowndes C.M., Shah K.V. Chapter 4: burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine 2006, 24(Suppl. 3):35-41.
24. Goldhaber-Fiebert J.D., Stout N.K., Salomon J.A., Kuntz K.M., Goldie S.J. Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16, 18 vaccination. J Natl Cancer Inst 2008, 100:308-320.
25. Goldie S.J., Kohli M., Grima D., Weinstein M.C., Wright T.C., Bosch F.X., et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 2004, 96:604-615.
26. Habbema D., De Kok I.M., Brown M.L. Cervical cancer screening in the United States and the Netherlands: a tale of two countries. Milbank Q 2012, 90:5-37.
27. Watson M., Saraiya M., Ahmed F., Cardinez C.J., Reichman M.E., Weir H.K., et al. Using population-based cancer registry data to assess the burden of human papillomavirus-associated cancers in the United States: overview of methods. Cancer 2008, 113(Suppl. 10):2841-2854.